Two recent phase II trials examined the efficacy of abiraterone acetate, a CYP17 inhibitor that impairs androgen synthesis, in patients with castration resistant prostate cancer used CTCs as efficacy markers. The gene discussed is CYP17A1; the disease is Familial prostate cancer.